Modern. Innovative. Integrated.
At InCevo, we are redefining drug development by seamlessly integrating strategic insight, scientific expertise, and advanced technology. From early discovery to regulatory approval, we offer end-to-end strategic solutions that accelerate timelines, reduce complexity, and drive meaningful impact.
With a global outlook and a data-driven approach, we craft forward-looking development strategies that anticipate regulatory pathways, enable smarter decisions, and support confident execution. Whether advancing promising drug candidates to first-in-human studies or navigating through proof-of-concept to late-stage submissions, we partner with biopharma innovators to bring breakthrough therapies to patients — faster, smarter, and with precision.
Founder & Chief Executive Officer
At InCevo, we set a new standard for partnership in today’s dynamic drug development landscape. Our mission is clear: to accelerate the journey from molecule to medicine by providing strong strategic program & portfolio leadership and integrating strategy, science, & advanced technologies.
We are passionate about collaboration, committed to excellence, and driven by the belief that smarter, faster development leads to better outcomes for patients.
Scientific Advisory Board (Upcoming...)
Why Partner With Us?
20+ Years of
Oncology Expertise
Proven leadership across early to late-stage oncology/hematology programs — from discovery to regulatory approval.
Strategic Leadership
for Diverse Modalities
Deep experience across both biologics and small molecules, monoclonal and multi-specific antibodies, Immune cell engagers, antibody-drug conjugates (ADCs), next-generation protein degraders and other modalities.
Cross-Functional
Depth That Delivers
Comprehensive understanding of clinical development, clinical pharmacology, pharmacometrics, translational science, regulatory strategy, and biometrics — aligned to accelerate decisions and outcomes.
Track Record of
Regulatory Success
Successfully delivered multiple INDs, BLAs/NDAs, and global regulatory submissions — including complex and accelerated pathways.
Science-Led,
Strategy-Driven
Our differentiator: strategic foresight rooted in science — enabling smarter trial designs, faster development, and de-risked pipelines.
Accelerated Execution
Without Compromise
We combine speed, precision, and quality — with adaptive approaches tailored to each molecule’s path.